Analysts say Medicare decision could spell the demise of Biogen's Alzheimer's drug; If government insurance coverage is limited to patients in clinical trials, the prospects for a treatment touted as a blockbuster last year will be dim.

Press/Media

Period12 Jan 2022

Media coverage

1

Media coverage

  • TitleAnalysts say Medicare decision could spell the demise of Biogen's Alzheimer's drug; If government insurance coverage is limited to patients in clinical trials, the prospects for a treatment touted as a blockbuster last year will be dim.
    Media name/outletbostonglobe.com
    Country/TerritoryUnited States
    Date12/01/22
    PersonsSamuel Gandy